Spinal injection aims to slow ALS in early trial
Disease control
Not yet recruiting
This study tests a single injection of TRCN-1023 into the spinal fluid of adults with ALS. The goal is to see if it is safe and shows early signs of slowing the disease over 24 weeks. Participants are randomly assigned to receive the drug or a placebo, and neither they nor their …
Phase: PHASE1, PHASE2 • Sponsor: Trace Neuroscience, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC